Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 22;36(2):261-270.
doi: 10.1515/reveh-2020-0051. Print 2021 Jun 25.

Mechanistic targets for BPH and prostate cancer-a review

Abhishek Shah  1 , Aarti Abhishek Shah  2 , Nandakumar K  2 , Richard Lobo  1
Affiliations
Free article
Review

Mechanistic targets for BPH and prostate cancer-a review

Abhishek Shah et al. Rev Environ Health. .
Free article

Abstract

All men, almost, suffer from prostatic disorders in average life expectancy. In the year of 1950s, the first autopsy of prostate gland discovered the link between Benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa). After that, many histology, biochemistry, epidemiology studies explained the association and associated risk factor for the same. From the various scientific evidence, it is proved that both diseases share some common transcription factors and signalling pathways. Still, BPH cannot be considered as the first step of PCa progression. To define, the relationship between both of the diseases, a well-defined large epidemiological study is needed. Along with androgen signalling, imbalanced apoptosis, oxidative stress, and microbial infection also crucial factors that significantly affect the pathogenesis of BPH. Various signalling pathways are involved in the progression of BPH. Androgen signalling is the driving force for the progress of PCa. In PCa androgen signalling is upregulated as compared to a healthy prostate. Some dominant Androgen-regulated genes and their functions have been discussed in this work.

Keywords: BPH; FKBP5; TGF β signalling; androgen signalling; prostate cancer.

PubMed Disclaimer

References

    1. Sommers, SC. Endocrine changes with prostatic carcinoma. Cancer 1957;10:345–58. https://doi.org/10.1002/1097-0142(195703/04)10:2<345::aid-cncr2820100....
    1. Orsted, DD, Bojesen, SE, Nielsen, SF, Nordestgaard, BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men. Eur Assoc Urol 2011;60:691–98. https://doi.org/10.1016/j.eururo.2011.06.016.
    1. Alcaraz, A, Hammerer, P, Tubaro, A, Schröder, FH, Castro, R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? findings of a literature review. Eur Urol 2009;55:864–75. https://doi.org/10.1016/j.eururo.2008.11.011.
    1. Guess, HA. Benign prostatic hyperplasia and prostate cancer. Epidemiol Rev 2001;23:152–8. https://doi.org/10.1093/oxfordjournals.epirev.a000782.
    1. Orsted, DD, Bojesen, SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013;10:49–54. https://doi.org/10.1038/nrurol.2012.192.

LinkOut - more resources